Oncology Breast Cancer    

FOI REFERENCE: 24146  FOI DATE: 4^th June 2024   

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

• Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) single agent  87 patients
• Abemaciclib + Fulvestrant  21 patients
• Alpelisib + Fulvestrant  * patients
• Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide  * patients
• Aromatase Inhibitor as a single agent  0 patients
• Atezolizumab * patients
• Capecitabine as a single agent   51 patients
• Carboplatin + Paclitaxel  * patients
• Eribulin as a single agent or in combination   * patients
• Everolimus + Exemestane  5 patients
• Fulvestrant as a single agent  31 patients
• Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)  81 patients
• Palbociclib + Fulvestrant   16 patients
• Parp Inhibitors (Olaparib/Talazoparib) 0 patients
• Pembrolizumab  11 patients
• Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)  5 patients
• Ribociclib + Fulvestrant  0 patients
• Sacituzumab Govitecan  8 patients
• Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent  51 patients
• Transtuzumab deruxtecan  8 patients
• Trastuzumab as a single agent or in combination  49 patients
• Trastuzumab emtansine 0 patients
• Any other active systemic anti-cancer therapy 

Zometa  75 patients

Denosumab 157 patients

*This relates to low numbers between 1 and 4. Under section 40 (ii) of the Freedom of Information Act 2000, statistically low numbers that potentially identify personal data are required to be withheld because of the Trusts obligation to protect personal data under the Data Protection Act 2018